HeartBeam Inc. BEAT Archives

ThursdayApr 30, 2026 9:20 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. To view the full press release, visit https://ibn.fm/yN939 About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting…

ThursdayApr 23, 2026 12:27 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move, “highlights HeartBeam’s growing focus on artificial intelligence (‘AI’)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions. The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management.” To view the…

FridayApr 17, 2026 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes To view the full press release, visit https://ibn.fm/9iNYY About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the…

WednesdayApr 15, 2026 9:15 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company and the final size and terms subject to market conditions. The company said it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes, with Titan Partners, a division of…

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

FridayMar 13, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, reported financial and operational results for the fourth quarter and full year ended Dec. 31, 2025, highlighting progress toward commercialization following U.S. Food and Drug Administration ("FDA") 510(k) clearance of its 12-lead electrocardiogram ("ECG") synthesis software in December 2025. The company has initiated a limited market launch targeting concierge and preventive cardiology groups and secured its first commercial partnership with ClearCardio(TM), while also enrolling initial patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. Additional developments include completion…

MondayMar 09, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Moves Forward Focused on Advancing Portable, High-Fidelity Cardiac Monitoring

The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions. HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care. Looking forward, HeartBeam is focused on advancing both its hardware and software platforms. HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring…

WednesdayMar 04, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio as First Customer and Strategic Investor

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced a commercial partnership with ClearCardio(TM), a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam’s first commercial customer and plans to make an investment in the company, underscoring strategic alignment. The staged rollout will integrate HeartBeam’s synthesized 12-lead ECG technology into ClearCardio’s cardiac prevention program for arrhythmia assessment, enabling patients to capture clinical-grade ECG readings from home using HeartBeam’s patented cable-free 3D ECG system. Structured as a Letter of Intent outlining subscription-based…

TuesdayMar 03, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization. Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.” The research report underscores the company’s targeted go-to-market strategy. Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing…

ThursdayFeb 12, 2026 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum. HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through…

Site Search

Company Search

Tag: HeartBeam Inc. BEAT